{"nctId":"NCT02173158","briefTitle":"Efficacy and Safety of Lomitapide in Japanese Patients With HoFH on Concurrent Lipid-Lowering Therapy","startDateStruct":{"date":"2014-04-02","type":"ACTUAL"},"conditions":["Familial Hypercholesterolemia - Homozygous"],"count":9,"armGroups":[{"label":"lomitapide","type":"EXPERIMENTAL","interventionNames":["Drug: lomitapide"]}],"interventions":[{"name":"lomitapide","otherNames":["Juxtapid, Lojuxta"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Japanese male and female patients aged ≥ 18 years of age who are receiving maximally tolerated, stable, lipid-lowering therapy\n2. Diagnosis of functional HoFH\n3. Body weight ≥ 40 kg and \\< 136 kg\n4. Negative pregnancy test at screening\n\nExclusion Criteria:\n\n1. Uncontrolled hypertension\n2. History of chronic renal insufficiency\n3. History of biopsy proven cirrhosis or abnormal liver function tests (LFTs) at screening\n4. Any major surgical procedure occurring \\< 3 months prior to the screening visit\n5. Cardiac insufficiency\n6. Previous organ transplantation\n7. History of a non-skin malignancy within the previous 3 years\n8. Patients who are not able to limit their alcohol intake\n9. Participation in an investigational drug study within 6 weeks prior to the screening visit\n10. Known significant gastrointestinal bowel disease\n11. Nursing mothers\n12. Serious or unstable medical or psychological conditions\n13. Requirement for certain prohibited medications known to be potentially hepatotoxic\n14. Use of strong or moderate inhibitors of CYP3A4\n15. Use of simvastatin at doses \\>10 mg per day\n16. Documented diagnosis of any liver disease","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change in LDL-C","description":"Mean percent change from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-42.2","spread":"18.16"}]}]}]},{"type":"SECONDARY","title":"Change in Total Cholesterol","description":"Mean percent change from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-25.9","spread":"18.57"}]}]}]},{"type":"SECONDARY","title":"Change in Apo B","description":"Mean percent change from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-41.4","spread":"21.90"}]}]}]},{"type":"SECONDARY","title":"Change in Triglycerides","description":"Mean percent change from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-44.4","spread":"12.70"}]}]}]},{"type":"SECONDARY","title":"Change in Non-HDL-C","description":"Mean percent change from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-34.6","spread":"22.50"}]}]}]},{"type":"SECONDARY","title":"Change in VLDL-C","description":"Mean percent change from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-44.8","spread":"12.05"}]}]}]},{"type":"SECONDARY","title":"Change in Lp(a)","description":"Mean percent change from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-27.2","spread":"23.50"}]}]}]},{"type":"SECONDARY","title":"Change in HDL-C","description":"Mean percent change from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":"19.64"}]}]}]},{"type":"SECONDARY","title":"Change in Apo AI","description":"Mean percent change from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.8","spread":"11.61"}]}]}]},{"type":"SECONDARY","title":"Change in LDL-C","description":"Mean percent change from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-37.5","spread":"24.21"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":9},"commonTop":["Diarrhoea","Nasopharyngitis","Anaemia","Liver function test abnormal","Nausea"]}}}